Abbisko Therapeutics Co, Ltd

This study is testing whether adding the experimental drug ABSK-011 to standard supportive care helps control advanced liver cancer better than supportive care alone. It's for patients whose cancer has worsened despite previous treatments and who have a specific biomarker called …

This is the first time researchers are testing the experimental drug ABSK131 in people. The study aims to find a safe dose and see if it helps control advanced cancers that have a specific genetic change called MTAP deficiency. It will enroll 266 adults with various solid tumors …

This study aims to collect detailed information about growth, health complications, and quality of life in children with achondroplasia. Researchers will follow 260 children aged 2.5 to 11 years for 6 months to 2 years to better understand the natural course of this condition. Th…

This early-stage trial is testing a new oral medication called ABSK-011 in people with advanced solid tumors, particularly liver cancer. Researchers want to find the safest dose and see how the drug moves through the body. The study will enroll 200 patients who have tried standar…

This is an early-stage study to test the safety and determine the best dose of a new oral medication called ABSK021 in people with advanced solid tumors that have stopped responding to standard treatments. The trial will enroll about 276 participants, including those with a rare …

This study is testing a new oral drug called ABSK141 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to find a safe dose, see how the body processes the drug, and check if it can help control cancers like colorectal, l…